Steven Cohen Aligos Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.87 - $2.11 $787,914 - $1.91 Million	-905,649 Reduced 99.97%	247 $0
Q4 2022 Feb 14, 2023	SELL	$0.89 - $28.0 $9,914 - $311,920	-11,140 Reduced 1.21%	905,896 $860,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $124,058 - $3.22 Million	117,036 Added 14.63%	917,036 $1.01 Million
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $1.43 Million - $8.41 Million	689,512 Added 624.06%	800,000 $1.72 Million
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $151,398 - $233,295	13,188 Added 13.55%	110,488 $1.31 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $1.42 Million - $1.72 Million	97,300 New	97,300 $1.51 Million

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.66B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.